XBIO - Xenetic Biosciences, Inc.
1.3800 +0.03 (2.22%)
Pre-Market: 9:06AM EDT
| Previous Close | 1.3100 |
| Open | 1.2200 |
| Bid | 1.4000 x 900 |
| Ask | 1.4100 x 900 |
| Day's Range | 1.1900 - 1.4200 |
| 52 Week Range | 0.9930 - 44.4000 |
| Volume | 1,360,668 |
| Avg. Volume | 607,532 |
| Market Cap | 7.605M |
| Beta (3Y Monthly) | 2.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.3230 |
| Earnings Date | Aug 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- ACCESSWIRE
Xenetic Biosciences, Inc. to Present at BIO Investor Forum
FRAMINGHAM, MA / ACCESSWIRE / October 16, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic, will present at BIO Investor Forum on Wednesday, October 23, 2019 at 2:45 PM PT in San Francisco, CA. As part of his presentation, Mr. Eisenberg will provide a Company overview and discuss the Company's novel CAR T platform technology, called "XCART," a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Non-Hodgkin lymphomas.
- ACCESSWIRE
Xenetic Biosciences, Inc. Provides Business Outlook
FRAMINGHAM, MA / ACCESSWIRE / October 8, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, today provided a business outlook. "2019 is proving to be a transformational year for Xenetic, marked by the shift in our corporate strategy with our entry into the CAR T arena through the acquisition of XCART.
- ACCESSWIRE
Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform
FRAMINGHAM, MA / ACCESSWIRE / July 22, 2019 / Xenetic Biosciences, Inc. (XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it closed its previously announced $15.0 million underwritten public offering. In conjunction with the closing of the offering, Xenetic completed its previously announced acquisition of the novel CAR T (“Chimeric Antigen Receptor T Cell”) platform technology, called “XCART,” a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, which has demonstrated proof-of-mechanism in B-cell Non-Hodgkin lymphomas.
- ACCESSWIRE
Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering
FRAMINGHAM, MA / ACCESSWIRE / July 17, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced the pricing of an underwritten public offering of 2,300,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to 2,300,000 shares of the Company’s common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $6.50 per share and warrant.
- Benzinga
Xenetic Biosciences Shares Surge After Biotech Prices Common Stock, Warrant Offering
Nano-cap biotech Xenetic Biosciences Inc (NASDAQ: XBIO )'s stock was rallying Friday following an announcement concerning pricing for its previously announced offering of common stock and accompanying ...
- ACCESSWIRE
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
FRAMINGHAM, MA / ACCESSWIRE / June 24, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), today announced it will effect a one-for-twelve reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of Nevada, the reverse stock split will be effective at 12:01 a.m., Eastern Time, on June 25, 2019. Xenetic expects that upon the opening of trading on June 25, 2019, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol "XBIO" and the new CUSIP number 984015 503.
- Simply Wall St.
Introducing Xenetic Biosciences (NASDAQ:XBIO), The Stock That Collapsed 98%
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held...
- Benzinga
The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...
- ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update
FRAMINGHAM, MA / ACCESSWIRE / May 13, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its financial results for the quarter ended March 31, 2019 and provided a corporate update. With the anticipated closing of our acquisition of XCART, our differentiated CAR T platform technology, on track for this quarter, I believe Xenetic will be well positioned to drive momentum in the innovation and development of new oncology therapeutics where there remains significant unmet need," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.
- ACCESSWIRE
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.
FRAMINGHAM, MA / ACCESSWIRE / May 2, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has appointed Guenther Koehne, M.D., Ph.D. to the Company's Scientific Advisory Board. Dr. Guenther Koehne is an internationally recognized cancer specialist and current Chief of Blood & Marrow Transplant and Hematologic Oncology at the Miami Cancer Institute.
- ACCESSWIRE
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update
FRAMINGHAM, MA / ACCESSWIRE / April 1, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its financial results for the year ended December 31, 2018. Xenetic also provided a corporate update and reviewed plans related to the Company's recently announced agreement to acquire a novel CAR T ("Chimeric Antigen Receptor T Cell") platform technology, called "XCART", as well as its oncology therapeutic XBIO-101 (sodium cridanimod), a small-molecule immunomodulator and interferon inducer which, in preliminary studies has been shown to increase progesterone receptor ("PrR") expression in endometrial tumor tissue.
- ACCESSWIRE
Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering
FRAMINGHAM, MA / ACCESSWIRE / March 5, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on the acquisition, research and development of novel oncology therapeutics, including next-generation cellular immunotherapies for difficult to treat cancers, including B-cell Lymphomas, as well as improved biologic drugs, today announced it has entered into a securities purchase agreement with a single accredited institutional investor to purchase approximately $3.1 million of the Company’s common stock (the "Common Stock") (or pre-funded warrants to purchase Common Stock in lieu thereof) in a registered direct offering (the "Offering") and warrants to purchase shares of Common Stock in a concurrent private placement. The combined purchase price for one share of Common Stock (or pre-funded warrants to purchase Common Stock in lieu thereof) and each warrant will be $2.00.
- ACCESSWIRE
Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform
LEXINGTON, MA / ACCESSWIRE / March 4, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its agreement to acquire the novel CAR T ("Chimeric Antigen Receptor T Cell") platform technology, called "XCART," a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Non-Hodgkin lymphomas. The XCART technology, developed by The Scripps Research Institute ("Scripps") in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells.
- Simply Wall St.
What Investors Should Know About Xenetic Biosciences Inc’s (NASDAQ:XBIO) Financial Strength
Xenetic Biosciences Inc (NASDAQ:XBIO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is XBIO Read More...
